Skip to content

Psilocybin research published in 2026

Page 20 of 25: studies 381 to 400 of 481, newest first. Back to the psilocybin overview

Studies

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression

Journal of Affective Disorders February 12, 2026 Erica Kaczmarek, Nelson Rodriguez, Noah Chisamore et al.

Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary analysis aimed to evaluate the effects of psilocybin-assisted psychotherapy (PAP) on anhedonia severity in individuals with treatment-resistant depression (TRD). Participants (n = 30) with TRD and a primary diagnosis of Major Depressive Disorder or...

Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice

Molecular Psychiatry February 12, 2026 Sixtine Fleury, Katherine M. Nautiyal correction

should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral and neural effects of psilocybin in mice."The final sentence of the Introduction should have read "Our findings suggest that the 5-HT1BR influences brain-wide neural changes following psilocybin administration and may contribute to its enduring...

Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study

Journal of Psychedelic Studies February 12, 2026 Matthew Hicks, Olivia Hicks, Ryan Bradley et al. 2 citations

Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. This study was designed to test the feasibility of conducting group psilocybin therapy in low-income adults with depression in Oregon's regulated psilocybin program. Methods An open label, uncontrolled design was used. After a medical screening...

DOI: 10.1556/2054.2026.00485 (opens in new tab) Psilocybin Adverse effect Depression economics Population +6

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD

February 11, 2026 Sarah Shnayder, Gabrielle Agin-Liebes, Troy Hubert et al. preprint

Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD)....

Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization

Zenodo (CERN European Organization for Nuclear Research) February 6, 2026 Zen Revista preprint

Psychedelic compounds, particularly psilocybin, have demonstrated remarkable therapeutic potential for mental health disorders through mechanisms involving structural neural plasticity. This comprehensive review examines recent breakthrough research revealing how psilocybin triggers activity-dependent rewiring of large-scale cortical networks. Using monosynaptic rabies viral tracing,...

India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.

Indian Journal of Psychological Medicine February 5, 2026 Ashlyn Tom, B. Sai Chaitanya Reddy, Manik Inder Singh Sethi et al.

The “entourage effect,” well-documented in cannabis research, remains a hypothesis requiring validation in psilocybin mushrooms. Whether the complex interplay among multiple bioactive compounds (including psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and various alkaloids) produces synergistic effects distinct from those of isolated psilocybin remains a critical empirical...

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.

Journal of Psychopharmacology February 5, 2026 Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.

Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...

Acute psilocin increased cortical activity in rat

Frontiers in Neuroscience February 4, 2026 Junhong Liu, Y. Lynn Wang, Ke Xia et al.

Psilocin, a naturally occurring hallucinogenic component of magic mushrooms, exerts notable psychoactive effects in both humans and rodents. However, the underlying mechanisms remain not fully understood. Blood-oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) is a valuable tool in many preclinical and clinical trials for investigating changes of brain activity and...

DOI: 10.3389/fnins.2026.1593703 (opens in new tab) Retrosplenial cortex Cortex anatomy Posterior cingulate Cerebral cortex +6

Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence

Exploratory Research in Clinical and Social Pharmacy February 4, 2026 Shreya Shiju, Rohan Tirumala, Elliot Marseille

Background: As public and scientific interest in psychedelics grows, unsupervised use for health purposes is increasing. In the U.S., past-year hallucinogen use nearly doubled from 2015 to 2023. Many individuals report self-treating physical or psychological symptoms without medical supervision using psychedelics—a practice termed self-medication. Despite this trend, review-level syntheses...

MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.

Biological Psychiatry February 3, 2026 Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal et al.

Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. This study investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioning. Adult male...

Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study

Psychedelic Medicine February 3, 2026 Anton T. Gregersen, Tobias P. Whelan, Caroline T. Golden et al. 2 citations

Introduction: Cognitive flexibility is essential for behavioral adaptation in response to environmental changes and is impaired in various neuropsychiatric disorders. The serotonergic psychedelic psilocybin has shown potential in enhancing cognitive flexibility, although with mixed results. In this study, we investigated the effects of psilocybin on cognitive flexibility in rats using a...

Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia

Psychedelics February 3, 2026 Sheida Shadani, Erika Greaves, Zane B. Andrews et al.

Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder, and anorexia nervosa (AN). These disorders often share social deficits that may be effectively alleviated by psychedelics considering their use has been linked with emotional empathy and enhanced social cognition. However,...

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Molecular Psychiatry February 3, 2026 Pablo Mallaroni, S. Parker Singleton, Natasha L. Mason et al.

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

Psychiatry Research February 2, 2026 Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al. 1 citation

Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial

Mendeley Data February 2, 2026 Matthew Johnson

BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abuse. Most smoking cessation interventions result in modest long-term success rates. A pilot study in 15 treatment-resistant smokers found psilocybin with cognitive behavioral therapy resulted in 80% point-prevalence abstinence rates at 6 months....

DOI: 10.17632/psdmryynyw.3 (opens in new tab) Psilocybin Nicotine patch Abstinence Smoking cessation +4

Psychedelika und Entaktogene: Neue Hoffnung für therapieresistente Störungen?

Nervenheilkunde February 1, 2026 Dimitris Repantis, Michael Koslowski, Felix Betzler et al.

Zusammenfassung Psychedelika wie Psilocybin und LSD durchlaufen eine bemerkenswerte Geschichte, die von frühen psychiatrischen Anwendungen über den Freizeitgebrauch und die Prohibition in den 70er Jahre bis zur aktuellen Wiederentdeckung in klinischen Studien reicht. MDMA wird seit etwa 15 Jahren für die Behandlung der posttraumatischen Belastungsstörung evaluiert. In der Behandlung werden...

Love (Drugs), Happiness, and Morality.

Bioethics February 1, 2026 Vojin Rakić

Various authors, including myself, have argued that happiness and morality operate in a circularly supportive relationship. In this paper, love will be added to this relationship. The new triple correlation will be explored through the following lens: not only do love and happiness reinforce moral action, but they appear to be in a triple circularly supportive relationship. Moral behavior is...

Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy.

Brain and Behavior February 1, 2026 Rachel Ham, John Gardner, Adrian Carter et al. 1 citation

Although commonly used in psychedelic-assisted therapy, the role of therapeutic touch remains loosely defined and ethically sensitive. Gaining insight into how participants experience and interpret touch during psychedelic sessions is essential for informing safe and effective clinical practice. Participants were sampled from a large randomized clinical trial of psilocybin-assisted therapy that...

Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society February 1, 2026 Katarzyna Kała, Dorota Bederska‐łojewska, Jan Lazur et al.

The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the form of fungal fruiting bodies, this...